Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy
Тенектеплаза при ишемическом инсульте через 4,5–24 часа без тромбэктомии
2024-06-14
SCID: 54.1/tgb3zur9
Discuss with AI
Large-vessel occlusionLate-window thrombolysisModified Rankin ScalePerfusion imagingTenecteplase
Figures from the paper
Abstract (AI)
BACKGROUND: Tenecteplase is an effective thrombolytic agent for eligible patients with stroke who are treated within 4.5 hours after the onset of stroke. However, data regarding the effectiveness of tenecteplase beyond 4.5 hours are limited. METHODS: In a trial conducted in China, we randomly assigned patients with large-vessel occlusion of the middle cerebral artery or internal carotid artery who had salvageable brain tissue as identified on perfusion imaging and who did not have access to endovascular thrombectomy to receive tenecteplase (at a dose of 0.25 mg per kilogram of body weight; maximum dose, 25 mg) or standard medical treatment 4.5 to 24 hours after the time that the patient was last known to be well (including after stroke on awakening and unwitnessed stroke). The primary outcome was the absence of disability, which was defined as a score of 0 or 1 on the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability), at day 90. The key safety outcomes were symptomatic intracranial hemorrhage and death. RESULTS: A total of 516 patients were enrolled; 264 were randomly assigned to receive tenecteplase and 252 to receive standard medical treatment. Less than 2% of the patients (4 in the tenecteplase group and 5 in the standard-treatment group) underwent rescue endovascular thrombectomy. Treatment with tenecteplase resulted in a higher percentage of patients with a modified Rankin scale score of 0 or 1 at 90 days than standard medical treatment (33.0% vs. 24.2%; relative rate, 1.37; 95% confidence interval, 1.04 to 1.81; P = 0.03). Mortality at 90 days was 13.3% with tenecteplase and 13.1% with standard medical treatment, and the incidence of symptomatic intracranial hemorrhage within 36 hours after treatment was 3.0% and 0.8%, respectively. CONCLUSIONS: In this trial involving Chinese patients with ischemic stroke due to large-vessel occlusion, most of whom did not undergo endovascular thrombectomy, treatment with tenecteplase administered 4.5 to 24 hours after stroke onset resulted in less disability and similar survival as compared with standard medical treatment, and the incidence of symptomatic intracranial hemorrhage appeared to be higher. (Funded by the National Natural Science Foundation of China and others; TRACE-III ClinicalTrials.gov number, NCT05141305.).
Key Findings
1
Functional independence at 90 days occurred in 33.0% of tenecteplase-treated patients versus 24.2% receiving standard treatment (relative rate, 1.37; 95% CI, 1.04–1.81; P=0.03).
2
In Chinese patients with large-vessel occlusion and salvageable tissue 4.5–24 hours after last-known-well, tenecteplase improved 90-day functional independence versus standard medical treatment.
3
Ninety-day mortality was similar between tenecteplase and standard treatment: 13.3% versus 13.1%.
4
Symptomatic intracranial hemorrhage within 36 hours was more frequent with tenecteplase, occurring in 3.0% versus 0.8% with standard treatment.
5
The trial evaluated tenecteplase largely without thrombectomy: fewer than 2% of participants underwent rescue endovascular thrombectomy.
Research Object
Chinese patients with ischemic stroke due to large-vessel occlusion of the middle cerebral artery or internal carotid artery, with salvageable brain tissue, treated 4.5 to 24 hours after they were last known to be well without access to endovascular thrombectomy
Research Subject
The efficacy and safety of tenecteplase versus standard medical treatment, assessed by 90-day functional independence, symptomatic intracranial hemorrhage, and mortality
Publication Details
Publication Date
2024-06-14
Journal
Publisher
ISSN
Cited by
252
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai2
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association2019
Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection2024
Cited by13
2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association2026
Efficacy and Safety of Intravenous Thrombolysis in the Extended Time Window for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis2025
Safety and efficacy of intravenous thrombolytic therapy in the extended window up to 24 hours: A systematic review and meta‐analysis2024
Advances in intravenous thrombolysis with tenecteplase in the ultra-time window2026
Role of tenecteplase in ischemic stroke after 4.5 hours: an evaluation of the TRACE-III trial2024
DWI-FLAIR mismatch versus perfusion-based selection for extended window thrombolysis in acute ischemic stroke: a meta-analysis of randomized controlled trials2026
Gray zones in acute stroke reperfusion: bridging, distal medium vessel occlusion, and extended-window thrombolysis2026
Extending the Treatment Window for Intravenous Thrombolysis in Acute Ischemic Stroke: An Updated Systematic Review and Meta-Analysis2026
Tenecteplase in the Extended 4.5–24-Hour Window for Acute Ischemic Stroke: An Updated Meta-Analysis of RCTs with EVT-Stratified Subgroup Analysis2026
Extending the time window for intravenous tenecteplase in patients with distal medium vessel occlusions stroke: study protocol and rationale2026
Safety and efficacy of intravenous tenecteplase in patients with acute ischemic stroke in extended time window: systematic review and meta-analysis2025
Effect of Time Delay on Reperfusion After Tenecteplase in an Extended Time Window: Analysis From the CHABLIS‐T Trials2025
Efficacy and safety of tenecteplase administration in extended time window for acute ischemic stroke: An updated meta-analysis of randomized controlled trials2025